- Home
- TDTH vs QNCX Comparison
TDTH vs QNCX Comparison
Compare TDTH & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDTH
- QNCX
- Stock Information
- Founded
- TDTH 2014
- QNCX 2012
- Country
- TDTH Singapore
- QNCX United States
- Employees
- TDTH N/A
- QNCX N/A
- Industry
- TDTH
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TDTH
- QNCX Health Care
- Exchange
- TDTH NYSE
- QNCX Nasdaq
- Market Cap
- TDTH 42.7M
- QNCX 43.2M
- IPO Year
- TDTH 2024
- QNCX 2019
- Fundamental
- Price
- TDTH $0.36
- QNCX $1.06
- Analyst Decision
- TDTH
- QNCX Strong Buy
- Analyst Count
- TDTH 0
- QNCX 5
- Target Price
- TDTH N/A
- QNCX $8.00
- AVG Volume (30 Days)
- TDTH 914.5K
- QNCX 611.7K
- Earning Date
- TDTH 06-10-2025
- QNCX 05-13-2025
- Dividend Yield
- TDTH N/A
- QNCX N/A
- EPS Growth
- TDTH N/A
- QNCX N/A
- EPS
- TDTH N/A
- QNCX N/A
- Revenue
- TDTH $465,435.00
- QNCX N/A
- Revenue This Year
- TDTH N/A
- QNCX N/A
- Revenue Next Year
- TDTH N/A
- QNCX N/A
- P/E Ratio
- TDTH N/A
- QNCX N/A
- Revenue Growth
- TDTH N/A
- QNCX N/A
- 52 Week Low
- TDTH $0.20
- QNCX $0.51
- 52 Week High
- TDTH $4.74
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- TDTH N/A
- QNCX 51.30
- Support Level
- TDTH N/A
- QNCX $1.01
- Resistance Level
- TDTH N/A
- QNCX $1.06
- Average True Range (ATR)
- TDTH 0.00
- QNCX 0.11
- MACD
- TDTH 0.00
- QNCX 0.02
- Stochastic Oscillator
- TDTH 0.00
- QNCX 80.95
About TDTH TRIDENT DIGITAL TECH HOLDINGS LTD SPON ADS EACH REP 8 ORD CL B
Trident Digital Tech Holdings is principally engaged in the provision of business consulting service and IT customization solutions in the Republic of Singapore.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.